<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181127</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001663/MGH</org_study_id>
    <nct_id>NCT02181127</nct_id>
  </id_info>
  <brief_title>Closed-Loop Glucagon Administration For Hypoglycemia Treatment</brief_title>
  <official_title>Closed-Loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that a wearable automated bionic pancreas system that
      automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for
      people with type 1 diabetes &gt; 21 years old.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl</measure>
    <time_frame>From t=0 to study stop after 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time With CGM Glucose Less Than 70 mg/dl Overnight and During Daytime</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Episodes With CGMG &lt; 50 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Episodes With CGMG &lt; 60 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Episodes With CGMG &lt; 70 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From All CGMG Measurements.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measurements adjusted for the frequency of measurement (i.e. modeled so that more frequent measurements at the time of hypoglycemia and exercise will not skew the mean):
&lt; 70 mg/dl,70-120 mg/dl,70-180 mg/dl, &gt;180 mg/dl, &gt;250 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Mean CGMG &lt; 154mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CGMG During Exercise</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Relative Deviation (MARD) vs. Subset of BG Measurements Before Meals and at Bedtime</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MARD vs. All BG Measurements</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Events as Determined From BG Measurements</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average BG as Determined From the Measurements Taken Before Meals and Before Bedtime</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Above Subset of BG Values Less Than 70 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of All BG Values Less Than 70 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Study Days With Mean BG &lt; 154 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction Measurements Within Each of the Following Glucose Ranges as Determined From HemoCue Measurements Taken Before Meals and Before Bed: &lt; 70 mg/dl,70-120 mg/dl,70-180 mg/dl,&gt;180 mg/dl,&gt;250 mg/dl</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BG During Exercise</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Fraction of BG Values &lt; 70 During Exercise Fraction of BG Values &lt; 70 During Exercise</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Carbohydrate Interventions for Hypoglycemia</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Grams of Carbohydrate Taken for Hypoglycemia</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Total Daily Dose</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Number of Carbohydrate Interventions for Hypoglycemia During the Daytime (7:00 AM - 11:00 PM)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Grams of Carbohydrate Taken for Hypoglycemia During the Daytime (7:00 AM - 11:00 PM)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Carbohydrate Interventions for Hypoglycemia Overnight (11:00 PM - 7:00 AM)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Grams of Carbohydrate Taken for Hypoglycemia Overnight (11:00 PM - 7:00 AM)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Glucagon Dosing (mcg/kg/24 Hours)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documented Episodes of Nausea and Fraction on Glucagon vs. Placebo Days</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Glucagon-only Bionic Pancreas (active)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon-only Bionic Pancreas (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucagon-only Bionic Pancreas</intervention_name>
    <description>A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.</description>
    <arm_group_label>Glucagon-only Bionic Pancreas (active)</arm_group_label>
    <arm_group_label>Glucagon-only Bionic Pancreas (placebo)</arm_group_label>
    <other_name>Boston University Bionic Pancreas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 years or older with type 1 diabetes for at least one year.

          -  Otherwise healthy (mild chronic disease such as asthma, hypertension, and depression
             will be allowed if well controlled).

          -  Self-reported frequency of documented hypoglycemia (BG &lt; 60 mg/dl) of at least 2 times
             per week

          -  Partial hypoglycemic unawareness (inconsistent symptoms with BG &lt; 50 mg/dl) or
             hypoglycemic unawareness (minimal or no symptoms with BG &lt; 50 mg/dl)

        Exclusion Criteria:

          -  Unable to provide informed consent.

          -  Unable to comply with study procedures.

          -  Current participation in another diabetes-related clinical trial other than one that
             is primarily observational in nature.

          -  Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the
             immediate future, or sexually active without use of contraception

          -  History of cystic fibrosis, pancreatitis, or other pancreatic disease other than type
             1 diabetes

          -  End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).

          -  Any known liver or biliary disease including cirrhosis, alcoholic liver disease,
             non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, any form of viral
             hepatitis.

          -  Congestive heart failure (established history of CHF, paroxysmal nocturnal dyspnea, or
             orthopnea).

          -  Acute illness or exacerbation of chronic illness at the time of the study.

          -  Seizure disorder or history of hypoglycemic seizure in the last 1 year

          -  History of pheochromocytoma. Fractionated metanephrines will be tested in patients
             with history increasing the risk for a catecholamine secreting tumor:

          -  Untreated or inadequately treated mental illness (indicators would include symptoms
             such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the
             last year).

          -  Current alcohol abuse (intake averaging &gt; 3 drinks daily in last 30 days) or substance
             abuse (any use within the last 6 months of controlled substances without a
             prescription).

          -  Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be
             susceptible to RF interference.

          -  History of adverse reaction to glucagon (including allergy) besides nausea and
             vomiting.

          -  Unwilling or unable to completely avoid acetaminophen during the study period.

          -  Any factors that, in the opinion of the principal investigator, would interfere with
             the safe completion of the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Russell, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://bionicpancreas.org</url>
    <description>Information about this and related studies</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 26, 2016</results_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>bionic pancreas</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>insulin</keyword>
  <keyword>glucagon</keyword>
  <keyword>continuous glucose monitoring (CGM)</keyword>
  <keyword>outpatient</keyword>
  <keyword>insulin pump</keyword>
  <keyword>glucagon pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>31 participants were enrolled in the trial, but only 22 participants actually participated. 4 subjects were not eligible to participate. The remaining 5 subjects that did not participate were considered &quot;back up&quot; or &quot;benched&quot; subjects who were eligible and willing to participate, but were not required to meet our desired total cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glucagon-only Bionic Pancreas</title>
          <description>Subjects will use the device every day and will fill the reservoir daily with glucagon or placebo (randomized, double blinded allocation for each day).
Glucagon-only Bionic Pancreas: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glucagon-only Bionic Pancreas</title>
          <description>Subjects will use the device every day and will fill the reservoir daily with glucagon or placebo (randomized, double blinded allocation for each day).
Glucagon-only Bionic Pancreas: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl</title>
        <time_frame>From t=0 to study stop after 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glucagon-only Bionic Pancreas</title>
            <description>Glucagon-only Bionic Pancreas delivered glucagon during 7 of the 14 days. The order of the glucagon days was randomized in blocks of 2, with no more than 2 days in a row of glucagon.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Glucagon-only Bionic Pancreas delivered placebo during 7 of the 14 days. The order of the placebo days was randomized in blocks of 2, with no more than 2 days in a row of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl</title>
          <units>mg/dl/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1015" spread="883.24"/>
                    <measurement group_id="O2" value="4375.68" spread="3058.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time With CGM Glucose Less Than 70 mg/dl Overnight and During Daytime</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Episodes With CGMG &lt; 50 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Episodes With CGMG &lt; 60 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Episodes With CGMG &lt; 70 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Time Spent Within Each of the Following Glucose Ranges as Determined From All CGMG Measurements.</title>
        <description>Measurements adjusted for the frequency of measurement (i.e. modeled so that more frequent measurements at the time of hypoglycemia and exercise will not skew the mean):
&lt; 70 mg/dl,70-120 mg/dl,70-180 mg/dl, &gt;180 mg/dl, &gt;250 mg/dl</description>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Mean CGMG &lt; 154mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean CGMG During Exercise</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Relative Deviation (MARD) vs. Subset of BG Measurements Before Meals and at Bedtime</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MARD vs. All BG Measurements</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Events as Determined From BG Measurements</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average BG as Determined From the Measurements Taken Before Meals and Before Bedtime</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Above Subset of BG Values Less Than 70 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of All BG Values Less Than 70 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Study Days With Mean BG &lt; 154 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction Measurements Within Each of the Following Glucose Ranges as Determined From HemoCue Measurements Taken Before Meals and Before Bed: &lt; 70 mg/dl,70-120 mg/dl,70-180 mg/dl,&gt;180 mg/dl,&gt;250 mg/dl</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BG During Exercise</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• Fraction of BG Values &lt; 70 During Exercise Fraction of BG Values &lt; 70 During Exercise</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Carbohydrate Interventions for Hypoglycemia</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Grams of Carbohydrate Taken for Hypoglycemia</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Total Daily Dose</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>• Number of Carbohydrate Interventions for Hypoglycemia During the Daytime (7:00 AM – 11:00 PM)</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Grams of Carbohydrate Taken for Hypoglycemia During the Daytime (7:00 AM – 11:00 PM)</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Carbohydrate Interventions for Hypoglycemia Overnight (11:00 PM – 7:00 AM)</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Grams of Carbohydrate Taken for Hypoglycemia Overnight (11:00 PM – 7:00 AM)</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Glucagon Dosing (mcg/kg/24 Hours)</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Documented Episodes of Nausea and Fraction on Glucagon vs. Placebo Days</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glucagon-only Bionic Pancreas</title>
          <description>Subjects will use the device every day and will fill the reservoir daily with glucagon or placebo (randomized, double blinded allocation for each day).
Glucagon-only Bionic Pancreas: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Steven J Russell</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1848</phone>
      <email>sjrussell@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

